Skip to main content
. 2017 Sep 8;8(54):92079–92089. doi: 10.18632/oncotarget.20759

Figure 1. Down-regulation of microRNA-92b-3p (miR-92b-3p) in the hypertrophic myocardium.

Figure 1

(A) Representative echocardiographs of mouse hearts. (B) The representative variables of echocardiograph assay in mice, including LVPWd, LVPWs, LVd, LVs, EF and FS. Data are shown as mean ± sem, *p < 0.05, **p < 0.01, ***p < 0.001 vs saline group. N = 6–8. (C) WGA staining assay of the hypertrophic myocardium of a mouse model of Ang-II-infusion-induced hypertrophy. The scale bar is 50 μm. (D) Expressions of ANP, ACTA1 and β-MHC in mouse myocardium by Western blot assay. (E) Expression of miR-92b-3p in mouse myocardium by RT-qPCR assay. Data are shown as mean ± sem, *p < 0.05, **p < 0.01, ***p < 0.001 vs sham group. N = 5–8. (F) WGA staining assay of the hypertrophic myocardium of patients with cardiac hypertrophy. The scale bar is 50 μm. (G) Expression of miR-92b-3p in human myocardium by RT-qPCR assay. Data are shown as mean ± sem, *p < 0.05, **p < 0.01 vs healthy control. N = 8.